Searching for the light, when darkness falls. The challenge of rare eye diseases becomes a short film with the #fightforlight campaign
A man finds himself lost in a wood, as night is falling. He finds a torch that shines a dim light and helps him move through the trees, looking for a way out of the blackness closing in on him. This is the opening scene of “In the Woods”, the short film commissioned by biopharmaceutical company Dompé to mark World Rare Disease Day, and presented today as part of the #fightforlight social media campaign.
Gabriele Mainetti, director of “They Call Me Jeeg”, is the man portraying the plight of people suffering from rare eye diseases. For these people, finding their way “back to the light” is complicated, sometimes leading down the wrong path and involving discomfort, tiredness and difficulties. Just like the protagonist, battling with distress, fatigue and being lost in an unfamiliar forest, searching for the light.
The rays of hope are metaphorically represented by the protagonist waking up the next day with his face bathed in light. “Any advance in research is a ray of hope”: the video ends with this message, to remind us that research can be a weapon to defeat the darkness of disease. “Considering that nature is anything but democratic, the objective to guarantee the same quality of life for everyone is deeply human”, said Gabriele Mainetti when speaking about his interpretation. “I believe in research and in its fight to help those who are lost in the darkness”.
Created by Saatchi & Saatchi, directed by Roberto Saku Cinardi and produced by Think Cattleya, the video is part of a constant commitment by Dompé to focus its research on identifying innovative treatments for rare diseases.
“With this campaign, we want to continue with the process of helping to shed light on the world of patients affected by rare diseases and their health needs”, explains Dompé CEO Eugenio Aringhieri. “The search for new treatment options is an important part of this world. This is a long and complex challenge, which in some ways evokes the experience of the protagonist in the video and which I am convinced we must pursue as a team, bringing together different perspectives around a single goal: the patient”.
“It is with great sense of responsibility that our company has embarked on the path of research for rare diseases and it is with this very spirit that we support and promote initiatives to raise awareness around this field”, said Sergio Dompé, President of the Dompé Group. “This is a world that is still not very well known today, which is why it is imperative that we continue to carry out research and inform on the value and benefits that this can have on people’s lives”.
In the field of rare eye diseases, Dompé is involved in research and development with the recombinant version of the human nerve growth factor (NGF), a biotech ophthalmic solution being studied in collaboration with clinical centres of excellence in Europe and the USA.
“Rare eye diseases are an area where patients are still waiting for many answers”, says Paolo Rama, Cornea and Ocular Surface Unit Director at the San Raffaele Research Hospital. “Italian research still owes a lot to studies conducted by Nobel Prize winner Rita Levi Montalcini on NGF, a protein naturally produced by the human body and responsible for the development, maintenance and survival of nerve cells, so we are waiting for the results of clinical trials we have conducted, which are expected to bring real innovation to certain areas of ophthalmology.”
“Progress in research and access to innovation are essential for people suffering from a rare disease and represent a real hope to fight and overcome the disease. As a civic movement aimed at protecting the rights of citizens and vulnerable people, Cittadinanzattiva encourages awareness-raising projects such as this. Being aimed at the general public, it can contribute to a greater awareness of rare diseases, which must become an increasingly key issue for public health”, explains Francesca Moccia, Deputy General Secretary of Cittadinanzattiva, who attended the preview of the video.
The short film, which is accompanied by the hashtag #fightforlight to allow sharing online and on social media, can be viewed on the Dompé YouTube channel, together with other backstage content related to the campaign. To view and share “In the Woods”: https://youtu.be/YIOA9ajZ0Gw
For further information, please visit: www.dompe.com
Laura Sprea, +39 02 58383567 | +39 3355745188
Corporate Communications Specialist
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13 | Pressemelding
Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 09:00 | Pressemelding
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom